Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JHL1101 vs Rituximab with CHOP in Previously Untreated DLBCL
NCT03670901Phase 3Terminated
- Sponsor
- Eden Biologics, Inc.
- Start
- Nov 2018
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rituximab biosimilar JHL1101 in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Eden Biologics, Inc. Primary endpoint: Overall response rate at 18 weeks. Started Nov 2018; status: terminated.
02
Drugs
rituximab biosimilar JHL1101
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03670901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03670901.